Skip to main content
. Author manuscript; available in PMC: 2012 Sep 16.
Published in final edited form as: Vaccine. 2011 Jul 27;29(40):7058–7066. doi: 10.1016/j.vaccine.2011.07.028

TABLE 2.

Response rates to HSV, CEF and CMV in subjects based on HSV serostatusa

HSV serostatus Total Subjects (n) Subjects with positive responses to:
HSV-2 CEF CMV PHA
n % n % n % n %
HSVneg 35 2 6% 22 63% 7 20% 35 100%
HSV-1+/2− 20 8 40% 10 60% 12 60% 20 100%
HSV-2+ 26 22 85% 18 69% 19 73% 26 100%
a

PBMC from HSVneg, HSV-1+/2− and HSV-2+ subjects were screened by IFN-γ ELISPOT for responses to HSV-2 (34 overlapping peptide pools), CEF and CMV peptide pools and PHA. Responses were considered positive if the SFC in the experimental well (average of 2 wells) was 4 times the median SFC in the DMSO control wells and ≥55 SFC/106 PBMC.

b

IFN-γ ELISPOT positivity to the CMV peptide pool was consistent with CMV serostatus: subjects with positive IFN-γ ELISPOT responses to the pp65 CMV peptide pool were CMV seropositive and subjects with negative IFN-γ ELISPOT responses to the CMV peptide pool were CMV seronegative.